<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hammel, Pascal</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Chemoradiotherapy Fails to Improve Overall Survival in LAPC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">Chemoradiotherapy is not superior to chemotherapy and the addition of erlotinib provides no benefit in the treatment of locally advanced pancreatic cancer. This article presents data from the Randomized Multicenter Phase 3 Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas [LAP07; NCT00634725; Hammel P et al. J Clin Oncol 2013 (suppl; abstr LBA4003)].</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>